10 domestic and multinational pharmaceutical companies jumped into the development of Humira biosimilar

With the patent expiration of AbbVie's 'Humira' ahead, 10 domestic and multinational pharmaceutical companies are jumping into development of Humira biosimilar.

Humira records annual domestic sales of 45 billion won and accounts for 30% of global rheumatoid arthritis therapeutics market. Therefore, if domestic biopharmaceutical company succeeds in development of biosimilar, it seems possible f...